Time to Cure and Predictive Factors Among Patients with Multi-Drug Resistance Tuberculosis in Puntland, Somalia: A Retrospective Cohort Study
Abstract
Background: Multi-drug-resistant tuberculosis, also known as MDR-TB, is caused by bacteria that are resistant to the most effective first-line anti-tuberculosis medications, which are rifampicin and isoniazid. MDR-TB is an increasing global concern, and its spread has varying cure times for patients affected. Thus, this study was intended to investigate the median time to cure and identify predictive factors for patients with MDR-TB in Puntland, Somalia.
Methods: A retrospective cohort study was carried out at the MDR-TB center in Galkayo, Puntland, Somalia between the years of July 2017 and August 2023. The study utilized data that were collected from the inquiry form and monitoring cards of a randomly selected sample of 130 patients over a 6-year period. The data were entered into Epi-Data version 4.3 and analyzed using R Programming version 4.4.0. Non-parametric methods were used to estimate the median time to cure for patients with MDR-TB. Semi-parametric and parametric models were employed to determine predictive factors that influence the time to cure for MDR-TB patients. The Akaike Information Criteria (AIC) and Bayesian Information Criteria (BIC) of different survival models were compared to select the model that offers the best fit.
Results: Out of the total of MDR-TB patients, 109(83.85%) were cured and 21(16.15%) were censored during the follow-up period. The median time to cure from MDR-TB was found to be 619 days which is approximately 20 months. In accordance with the AIC and BIC, the Log-logistic accelerated failure time model was the best fit for the data as compared to the other AFT models. The result of the Log-logistic AFT model revealed that age, sex, disease site, and comorbidities significantly affect the time to cure for MDR-TB. According to this study, older age with MDR-TB patients, male MDR-TB patients, MDR-TB patients with comorbid conditions, and extrapulmonary MDR-TB patients had a longer time to cure than their reference categories.
Conclusion: Based on the findings of the study, the median time to cure for patients with MDR-TB in Puntland was found to be 20 months. Sex, disease site, comorbidities and age were predictive factors of time to cure from MDR-TB.
Keywords:
Puntland State, Multi-drug resistance tuberculosis, Median time to cure, Log-logistic Accelerated Failure time modelDOI
https://doi.org/10.22270/jddt.v14i11.6885References
1. WHO G. Global tuberculosis report 2020. Glob Tuberc Rep. 2020;2020. https://www.who.int/teams/global-tuberculosis-programme/tb-reports
2. WHO. WHO consolidated guidelines on tuberculosis 2023.
3. Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, et al. Global Tuberculosis Report 2020-Reflections on the Global TB burden, treatment and prevention efforts. International journal of infectious diseases. 2021;113:S7-S12. https://doi.org/10.1016/j.ijid.2021.02.107 PMid:33716195 PMCid:PMC8433257
4. Du L, Zhang Y, Lv X, Duan Y, Shi X, Ji H, et al. Prevalence of multidrug-resistant tuberculosis in Dalian, China: a Retrospective Study. Infection and Drug Resistance. 2021:1037-47. https://doi.org/10.2147/IDR.S294611 PMid:33758518 PMCid:PMC7981151
5. WHO. Global Tuberculosis Report 2019. 2019. https://www.who.int/teams/global-tuberculosis-programme/tb-reports
6. Oladimeji O, Ushie BA, Udoh EE, Oladimeji KE, Ige OM, Obasanya O, et al. Psychosocial wellbeing of patients with multidrug resistant tuberculosis voluntarily confined to long-term hospitalisation in Nigeria. BMJ global health. 2016;1(3):e000006. https://doi.org/10.1136/bmjgh-2015-000006 PMid:28588950 PMCid:PMC5321341
7. WHO. Global tuberculosis report 2013. World Health Organization; 2013. Report No.: 9241564652. https://www.who.int/teams/global-tuberculosis-programme/tb-reports
8. WHO. Global Tuberculosis Report. 2017. https://www.who.int/teams/global-tuberculosis-programme/tb-reports
9. Organization WH. Global tuberculosis report 2013. 2013. https://www.who.int/teams/global-tuberculosis-programme/tb-reports
10. Kerubo G, Amukoye E, Niemann S, Kariuki S. Drug susceptibility profiles of pulmonary Mycobacterium tuberculosis isolates from patients in informal urban settlements in Nairobi, Kenya. BMC infectious diseases. 2016;16:1-7. https://doi.org/10.1186/s12879-016-1920-5 PMid:27756241 PMCid:PMC5070164
11. Wu S, Zhang Y, Sun F, Chen M, Zhou L, Wang N, et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. American journal of therapeutics. 2016;23(2):e521-e30. https://doi.org/10.1097/01.mjt.0000433951.09030.5a PMid:24284652
12. Limenih YA, Workie DL. Survival analysis of time to cure on multi-drug resistance tuberculosis patients in Amhara region, Ethiopia. BMC public health. 2019;19:1-11. https://doi.org/10.1186/s12889-019-6500-3 PMid:30732601 PMCid:PMC6367739
13. Abdo SS, Wanore DS, Teni DA, Ejamo LA. Modelling Time to Recovery from Multidrug Resistant Tuberculosis in Southern Ethiopia. Journal of Pharmaceutical Research International. 2024;36(6):88-103. https://doi.org/10.9734/jpri/2024/v36i67525
14. Sindani I, Fitzpatrick C, Falzon D, Suleiman B, Arube P, Adam I, et al. Multidrug-resistant tuberculosis, Somalia, 2010-2011. Emerging infectious diseases. 2013;19(3):478. https://doi.org/10.3201/eid1903.121287 PMCid:PMC3647667
15. Mohamed MA, Ali OA, Osman AM, Abatcha MG, Ahmed AA, Ali AM, et al. Assessment of drug-susceptible and multidrug-resistant tuberculosis (MDR-TB) in the Central Region of Somalia: A 3-year retrospective study. PLOS Global Public Health. 2023;3(9):e0002319. https://doi.org/10.1371/journal.pgph.0002319 PMid:37676848 PMCid:PMC10484424
16. Dirie AMH, Çolakoğlu S, Abdulle OM, Abdi BM, Osman MA, Shire AM, et al. Prevalence of multidrug-resistant TB among smear-positive pulmonary TB patients in Banadir, Somalia: a multicenter study. Infection and Drug Resistance. 2022:7241-8. https://doi.org/10.2147/IDR.S386497 PMCid:PMC9749408
17. Ali MM, Weldegebreal F, Kabew G, Urgesa K. Rifampicin resistant Mycobacterium tuberculosis and associated factors among presumptive pulmonary tuberculosis patients in Mogadishu, Somalia. SAGE Open Medicine. 2023;11:20503121221148603. https://doi.org/10.1177/20503121221148603 PMid:36643204 PMCid:PMC9834785
18. Puntlad Facts and Figures. Puntland Facts and Figures; Ministry of Planning and International Cooperation; Department of Statistics. 2017. https://bareedo.org/wp-content/uploads/2019/10/Puntland-Facts-and-Figures-2017-Year-book-2018-1.pdf
19. Cochran WG. Sampling techniques: john wiley & sons; 1977.
20. Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. European Respiratory Journal. 2017;49(3). https://doi.org/10.1183/13993003.02308-2016 PMid:28331043 PMCid:PMC5399349
21. Parmar MM, Sachdeva KS, Dewan PK, Rade K, Nair SA, Pant R, et al. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): evidence leading to policy enhancement. PloS one. 2018;13(4):e0193903. https://doi.org/10.1371/journal.pone.0193903 PMid:29641576 PMCid:PMC5894982
22. Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. The international journal of tuberculosis and lung disease. 2010;14(4):413-9.
23. Girum T, Tariku Y, Dessu S. Survival status and treatment outcome of multidrug resistant tuberculosis (MDR-TB) among patients treated in treatment initiation centers (TIC) in South Ethiopia: a retrospective cohort study. Annals of medical and health sciences research. 2017;7(5).
24. Mitku AA, Dessie ZG, Muluneh EK, Workie DL. Prevalence and associated factors of TB/HIV co-infection among HIV Infected patients in Amhara region, Ethiopia. African health sciences. 2016;16(2):588-95.
25. Hawulet M. Survival Analysis of Time to Recovery And Associated Factors of Tuberculosis Patients in Dessie Comprehensive Specialised Hospital, South Wollo, Ethiopia 2021
Published
Abstract Display: 43 
PDF Downloads: 221 PDF Downloads: 5 How to Cite
Issue
Section
Copyright (c) 2024 Mustafe Abdi Ali , Mohyadin Abdullahi Ahmed , Hassan Ahmed Hussein , Ahmed Mohammed Ibrahim
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.